Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31448305 | 1.00 | CES2 (0.47) | CES2CES1KEAP1MAOBMAOA | |
| SCHEMBL18070537 | 0.85 | BCL2L1 (0.41) | MAOBMAOATTRALDH1A1SMN1; SMN2 | |
| SCHEMBL27883282 | 0.83 | CES2 (0.50) | CES2CES1KEAP1MAOBTTR | |
| SCHEMBL16952267 | 0.83 | CES2 (0.40) | CES2CES1KEAP1TTRALDH1A1 | |
| SCHEMBL1150930 | 0.81 | KEAP1 (0.59) | CES2CES1KEAP1MAOBTTR | |
| SCHEMBL30762574 | 0.81 | KEAP1 (0.59) | CES2CES1KEAP1MAOBTTR | |
| SCHEMBL28423060 | 0.79 | CES2 (0.47) | CES2CES1KEAP1MAOBTTR | |
| SCHEMBL21510606 | 0.79 | CES2 (0.38) | CES2CES1KEAP1TTRANO1 | |
| SCHEMBL28966735 | 0.79 | CES2 (0.38) | CES2CES1KEAP1TTRANO1 | |
| SCHEMBL1804347 | 0.79 | KEAP1 (0.47) | CES2CES1KEAP1TTRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119876287-A | Fluorine-containing aromatic alcohol compound, and preparation method and application thereof | 上海泓博尚奕药物技术有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-111718913-B | Ketoreductase polypeptide and method for preparing (S) -1- (2-iodo-5-fluorophenyl) ethanol by catalyzing same | 尚科生物医药（上海）有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-119876287-A | Fluorine-containing aromatic alcohol compound, and preparation method and application thereof | 上海泓博尚奕药物技术有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119876287-A | Fluorine-containing aromatic alcohol compound, and preparation method and application thereof | 上海泓博尚奕药物技术有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | SHANGHAI UNIVERSITY OF MEDICINE & HEALTH SCIENCES (CN) | 2024-12-10 | — | — | US | disclosed |
| WO-2023196900-A9 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2023196900-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322797-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | CAMBREX CORPORATION | 2023-10-12 | — | — | US | disclosed |
| US-20230322797-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | CAMBREX CORPORATION | 2023-10-12 | — | — | US | disclosed |
| CN-111718913-B | Ketoreductase polypeptide and method for preparing (S) -1- (2-iodo-5-fluorophenyl) ethanol by catalyzing same | 尚科生物医药（上海）有限公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-111718913-B | Ketoreductase polypeptide and method for preparing (S) -1- (2-iodo-5-fluorophenyl) ethanol by catalyzing same | 尚科生物医药（上海）有限公司 | 2023-06-20 | — | — | CN | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| WO-2013187466-A1 | BRANCHED CHAIN ALKYL HETEROAROMATIC RING DERIVATIVE | 大正製薬株式会社 (JP) | 2013-12-19 | — | — | WO | disclosed |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013132376-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2566858-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | Pfizer Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | CES2 2854/4885CES1 2120/4885KEAP1 896/4885 |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | CES2 2854/4885CES1 2120/4885KEAP1 896/4885 |
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | IGF1R, TSHR, TRHR | CES2 4478/4885CES1 3026/4885KEAP1 4794/4885 |
| US-20230322797-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | CYP11B2, CYP4A11, CYP11B1 | CES2 434/4885CES1 155/4885KEAP1 547/4885 |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, ACVR1 | CES2 2687/4885CES1 1172/4885KEAP1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.